Ratish Krishnan is a Senior Strategy Consultant in the Novel Modalities BioProcessing group for the Americas. He is passionate about providing solutions to bring treatments to market. A Process Development Scientist by background, he has over 13 years of experience in vaccine, monoclonal antibodies and viral vector modalities from pre-clinical to late stage process characterization, validation and commercialization activities such as BLA authoring.

Oliver Rammo is leading the Novel Modality segment in the Purification R&D Group responsible for the development of novel purification strategies for the Viral and Gene Therapy market. Prior to his current role, he worked as Laboratory Manager and Application Engineer for the MilliporeSigma Life Science division. He joined

in 2012, working for Performance Materials Advanced Technologies in the field of printing formulations for photovoltaic applications. Oliver holds a BSc in Applied Life Science from the University of Kaiserslautern and an MSc in Molecular Biotechnology from the University of Frankfurt.